Migraine – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Migraine – Pipeline Review, H2 2019’, provides an overview of the Migraine pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Migraine, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Migraine and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”


– The report provides a snapshot of the global therapeutic landscape of Migraine

– The report reviews pipeline therapeutics for Migraine by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Migraine therapeutics and enlists all their major and minor projects

– The report assesses Migraine therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Migraine”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Migraine

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Achelios Therapeutics Inc

Acorda Therapeutics Inc

Allergan Plc

Allodynic Therapeutics LLC

Amgen Inc


Aptarion biotech AG

Asarina Pharma AB

Astrocyte Pharmaceuticals Inc

Avanir Pharmaceuticals Inc

Axsome Therapeutics Inc

Biohaven Pharmaceutical Holding Company Ltd

BioHealthonomics Inc

Blackthorn Therapeutics Inc

Cerecin Inc

CerSci Therapeutics Inc

Charleston Laboratories Inc

Citragen Pharmaceuticals Inc

Corium International Inc

Crossject SA

Curatis AG

CURx Pharmaceuticals Inc

DelNova Inc

Eli Lilly and Co

Epalex Corp

Exxel Pharma Inc

H. Lundbeck AS

Impel NeuroPharma Inc

InKemia IUCT Group SA

InStar Technologies AS

IntelGenx Corp

Invisio Ltd

Ionis Pharmaceuticals Inc

Klaria Pharma Holding AB

Lateral Pharma Pty Ltd

Living Cell Technologies Ltd

MannKind Corp

Medytox Inc

Merck & Co Inc

NAL Pharmaceuticals Ltd

NeurAxon Pharma Inc

NutriBand Inc

Old API Wind-down Ltd

OWP Pharmaceuticals Inc

Panaxia Pharmaceutical Industries Ltd

Pharmnovo AB

Pivot Pharmaceuticals Inc

Promius Pharma LLC

Qingdao Chia Tai Haier Pharmaceutical Co Ltd

RAFT Pharmaceuticals

Revance Therapeutics Inc

Sarfez Pharmaceuticals Inc

Satsuma Pharmaceuticals Inc

Seurat Therapeutics Inc

Shanghai Junshi Bioscience Co Ltd

Shin Nippon Biomedical Laboratories Ltd

Sorrento Therapeutics Inc

Sosei Heptares

Suda Pharmaceuticals Ltd

Terran Biosciences Inc

Teva Pharmaceutical Industries Ltd

Trevena Inc

TrioxBio Inc

Xenon Pharmaceuticals Inc

Xoc Pharmaceuticals Inc

Zosano Pharma Corp”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Migraine - Overview 6

Migraine - Therapeutics Development 7

Migraine - Therapeutics Assessment 20

Migraine - Companies Involved in Therapeutics Development 30

Migraine - Drug Profiles 49

Migraine - Dormant Projects 205

Migraine - Discontinued Products 210

Migraine - Product Development Milestones 211

Appendix 222

List of Tables

“List of Tables

Number of Products under Development for Migraine, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Migraine – Pipeline by Achelios Therapeutics Inc, H2 2019

Migraine – Dormant Projects, H2 2019

Migraine – Discontinued Products, H2 2019”


Discounts available for multiple report purchases.

+44 (0) 161 359 5414

Saved reports